The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.